High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast

Lee Schwartzberg, C. H. Weaver, L. Lewkow, B. McAneny, B. Zhen, R. Birch, W. H. West, K. W. Tauer, C. D. Buckner

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91%) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4%) infectious deaths after HDC. Twenty-four patients (43%) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34%. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median follow-up of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences.

Original languageEnglish (US)
Pages (from-to)981-987
Number of pages7
JournalBone Marrow Transplantation
Volume24
Issue number9
DOIs
StatePublished - Jan 1 1999

Fingerprint

Inflammatory Breast Neoplasms
Drug Therapy
Thiotepa
Carboplatin
Cyclophosphamide
Induction Chemotherapy
Disease-Free Survival
Recurrence
Combined Modality Therapy
Peripheral Blood Stem Cells

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. / Schwartzberg, Lee; Weaver, C. H.; Lewkow, L.; McAneny, B.; Zhen, B.; Birch, R.; West, W. H.; Tauer, K. W.; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 24, No. 9, 01.01.1999, p. 981-987.

Research output: Contribution to journalArticle

Schwartzberg, L, Weaver, CH, Lewkow, L, McAneny, B, Zhen, B, Birch, R, West, WH, Tauer, KW & Buckner, CD 1999, 'High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast', Bone Marrow Transplantation, vol. 24, no. 9, pp. 981-987. https://doi.org/10.1038/sj.bmt.1701965
Schwartzberg, Lee ; Weaver, C. H. ; Lewkow, L. ; McAneny, B. ; Zhen, B. ; Birch, R. ; West, W. H. ; Tauer, K. W. ; Buckner, C. D. / High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 9. pp. 981-987.
@article{852cf7af898b49ee88a779e2d94dba38,
title = "High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast",
abstract = "The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91{\%}) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4{\%}) infectious deaths after HDC. Twenty-four patients (43{\%}) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34{\%}. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median follow-up of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences.",
author = "Lee Schwartzberg and Weaver, {C. H.} and L. Lewkow and B. McAneny and B. Zhen and R. Birch and West, {W. H.} and Tauer, {K. W.} and Buckner, {C. D.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701965",
language = "English (US)",
volume = "24",
pages = "981--987",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast

AU - Schwartzberg, Lee

AU - Weaver, C. H.

AU - Lewkow, L.

AU - McAneny, B.

AU - Zhen, B.

AU - Birch, R.

AU - West, W. H.

AU - Tauer, K. W.

AU - Buckner, C. D.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91%) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4%) infectious deaths after HDC. Twenty-four patients (43%) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34%. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median follow-up of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences.

AB - The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91%) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4%) infectious deaths after HDC. Twenty-four patients (43%) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34%. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median follow-up of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences.

UR - http://www.scopus.com/inward/record.url?scp=0032714427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032714427&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701965

DO - 10.1038/sj.bmt.1701965

M3 - Article

VL - 24

SP - 981

EP - 987

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -